{"id":"cetuximab-oxaliplatin-leucovorin-5fu-irinotecan","safety":{"commonSideEffects":[{"rate":"45%","effect":"Diarrhea"},{"rate":"35%","effect":"Fatigue"},{"rate":"30%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) and inhibits its tyrosine kinase activity, thereby inhibiting tumor growth and angiogenesis. Oxaliplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting DNA replication and transcription. Leucovorin is a folate analog that inhibits the metabolism of 5-fluorouracil (5-FU) and irinotecan, allowing them to exert their cytotoxic effects on cancer cells. 5-FU is a thymidylate synthase inhibitor that works by inhibiting the synthesis of thymidine, a nucleotide required for DNA replication. Irinotecan is a topoisomerase I inhibitor that works by inhibiting the enzyme topoisomerase I, which is involved in DNA replication and transcription.","oneSentence":"Inhibits epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:50:27.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT07474727","phase":"PHASE2","title":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Multitude Therapeutics Inc.","startDate":"2026-04-01","conditions":"Colorectal Cancer","enrollment":180},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":750},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT00556413","phase":"PHASE2","title":"Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2005-09","conditions":"Colorectal Cancer","enrollment":42},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT03366155","phase":"PHASE2","title":"Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-24","conditions":"Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma","enrollment":24},{"nctId":"NCT06586515","phase":"PHASE1","title":"MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-12","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":630},{"nctId":"NCT05959356","phase":"PHASE2","title":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-09","conditions":"Metastatic Colorectal Cancer","enrollment":198},{"nctId":"NCT07204574","phase":"PHASE1, PHASE2","title":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-14","conditions":"CRC","enrollment":40},{"nctId":"NCT06967155","phase":"PHASE2","title":"A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-03-01","conditions":"Neoplasms","enrollment":23},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT03493048","phase":"PHASE2","title":"Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-04-15","conditions":"Colorectal Cancer, Liver Metastases","enrollment":146},{"nctId":"NCT07070713","phase":"PHASE2","title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-07-30","conditions":"Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy","enrollment":44},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT06928584","phase":"PHASE2","title":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-10","conditions":"Locally Recurrent Rectal Cancer","enrollment":221},{"nctId":"NCT01878422","phase":"PHASE3","title":"Sequential Treatment Strategy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2007-11","conditions":"Metastatic Colorectal Cancer","enrollment":376},{"nctId":"NCT04513951","phase":"PHASE2","title":"AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2020-04-01","conditions":"Metastatic Colorectal Cancer","enrollment":62},{"nctId":"NCT04687631","phase":"PHASE3","title":"Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-01-14","conditions":"Colorectal Cancer, Liver Metastases","enrollment":508},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT02563002","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-30","conditions":"Colorectal Carcinoma","enrollment":307},{"nctId":"NCT03164655","phase":"PHASE2","title":"Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-07-25","conditions":"Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT04034459","phase":"PHASE2","title":"FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2016-11-25","conditions":"Metastatic Colorectal Cancer","enrollment":109},{"nctId":"NCT05797883","phase":"PHASE2","title":"FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2022-08-01","conditions":"Unresectable or Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT05652894","phase":"PHASE3","title":"A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2022-12-20","conditions":"Metastatic Colorectal Cancer","enrollment":190},{"nctId":"NCT05103020","phase":"PHASE2","title":"Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2021-11-01","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT00381706","phase":"PHASE2","title":"Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-09-15","conditions":"Esophageal Cancer","enrollment":245},{"nctId":"NCT01276379","phase":"PHASE2","title":"Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab","status":"COMPLETED","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2011-01","conditions":"Colorectal Cancer","enrollment":221},{"nctId":"NCT01442935","phase":"PHASE2","title":"Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2011-02","conditions":"Colorectal Cancer","enrollment":256},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT03031444","phase":"PHASE2, PHASE3","title":"Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-01","conditions":"Colorectal Cancer Stage IV, Metastasis","enrollment":135},{"nctId":"NCT01703390","phase":"PHASE2","title":"Biomarker Directed Treatment in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2012-12-04","conditions":"Metastatic Colorectal Cancer","enrollment":47},{"nctId":"NCT01867697","phase":"PHASE2","title":"Nordic 8 - A Phase II Trial","status":"COMPLETED","sponsor":"Per Pfeiffer","startDate":"2012-05","conditions":"Metastatic Colorectal Cancer","enrollment":173},{"nctId":"NCT00079274","phase":"PHASE3","title":"Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-02","conditions":"Adenocarcinoma of the Colon, Stage III Colon Cancer","enrollment":3397},{"nctId":"NCT00265850","phase":"PHASE3","title":"Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2005-11","conditions":"Colorectal Cancer","enrollment":2334},{"nctId":"NCT02063529","phase":"PHASE2","title":"FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-02","conditions":"Metastatic Colorectal Cancer","enrollment":101},{"nctId":"NCT03022734","phase":"PHASE2","title":"Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2016-09","conditions":"Rectal Cancer, Metastatic","enrollment":40},{"nctId":"NCT01923987","phase":"PHASE2","title":"Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis","status":"UNKNOWN","sponsor":"Korea Cancer Center Hospital","startDate":"2012-08","conditions":"Rectal Cancer, Liver Metastasis, Lung Metastasis","enrollment":39},{"nctId":"NCT01802645","phase":"PHASE2","title":"Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2013-03","conditions":"Colorectal Cancer","enrollment":91},{"nctId":"NCT01640444","phase":"PHASE2","title":"Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2012-07","conditions":"Colorectal Cancer Metastatic","enrollment":240},{"nctId":"NCT00551213","phase":"PHASE2","title":"A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-21","conditions":"Colorectal Cancer","enrollment":67},{"nctId":"NCT00077233","phase":"PHASE3","title":"FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-12","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT03391843","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2017-12-01","conditions":"Rectal Cancer Stage III","enrollment":100},{"nctId":"NCT01134666","phase":"","title":"An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-11-30","conditions":"Colorectal Neoplasms","enrollment":165},{"nctId":"NCT01858662","phase":"PHASE2","title":"Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2014-01","conditions":"Metastatic Colorectal Cancer","enrollment":4},{"nctId":"NCT00755118","phase":"PHASE2","title":"Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc","status":"TERMINATED","sponsor":"University Hospital of Crete","startDate":"2008-10","conditions":"Colorectal Cancer","enrollment":24},{"nctId":"NCT00689624","phase":"PHASE2","title":"Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer","status":"COMPLETED","sponsor":"University Hospital of Crete","startDate":"2007-07","conditions":"Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT02515734","phase":"PHASE2","title":"A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab","status":"UNKNOWN","sponsor":"Japan Clinical Cancer Research Organization","startDate":"2015-08","conditions":"Colorectal Cancer","enrollment":360},{"nctId":"NCT01030042","phase":"PHASE3","title":"Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients","status":"COMPLETED","sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","startDate":"2009-09","conditions":"Metastatic Colorectal Cancer","enrollment":110},{"nctId":"NCT00778830","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-02","conditions":"Metastatic Colorectal Cancer","enrollment":289},{"nctId":"NCT00286130","phase":"PHASE2","title":"Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Central European Cooperative Oncology Group","startDate":"2005-07","conditions":"Metastatic Colorectal Cancer","enrollment":150},{"nctId":"NCT00502567","phase":"PHASE1","title":"A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-01","conditions":"Advanced Solid Tumor","enrollment":104},{"nctId":"NCT00513266","phase":"PHASE2","title":"Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2007-06","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":35},{"nctId":"NCT00422773","phase":"PHASE1, PHASE2","title":"Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2007-01","conditions":"Metastatic Colorectal Cancer","enrollment":21},{"nctId":"NCT00153998","phase":"PHASE2","title":"Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2004-11","conditions":"Colorectal Cancer, Liver Metastases","enrollment":135}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan","genericName":"Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan","companyName":"Central European Cooperative Oncology Group","companyId":"central-european-cooperative-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinases. Used for Colorectal cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}